Aerie Pharma (AERI) PT Lowered to $48 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Aerie Pharma (AERI) PT Lowered to $48 at Needham & Company
October 30, 2019 7:30 AM EDT
DURHAM, N.C.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its third quarter 2019 financial results will be released after the market closes on Wednesday, November 6, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Companys financial results and provide a general business... More
October 30, 2019 6:30 AM EDT
DURHAM, N.C.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., Ph.D., Aeries Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on November 11, 2019 and will direct the Companys preclinical... More
